| Literature DB >> 33867791 |
Demet Turan1, Efsun Gonca Uğur Chousein1, Aysu Sinem Koç2, Mustafa Çörtük1, Zeynep Yıldırım1, Bariş Demirkol1, Mehmet Akif Özgül1, Halit Çınarka1, Neslihan Akalın3, Aytül Hande Yardımcı4, Erdoğan Çetinkaya1.
Abstract
BACKGROUND AND OBJECTIVES: Transbronchial cryobiopsy (cryo-TBB) is increasingly being used in the diagnosis of diffuse parenchymal lung diseases (DPLD). Varying diagnostic success and complication rates have been reported. Herein we report our experience with cryo-TBB, focusing on diagnostic yield, factors affecting diagnosis, and safety.Entities:
Keywords: Transbronchial cryobiopsy; bronchoscopy; diagnostic yield; parenchymal lung diseases
Year: 2021 PMID: 33867791 PMCID: PMC8050620 DOI: 10.36141/svdld.v38i1.11029
Source DB: PubMed Journal: Sarcoidosis Vasc Diffuse Lung Dis ISSN: 1124-0490 Impact factor: 0.670
Figure 1.Diagnostic algorithm of the patients
Figure 2.a) The flexible 1.9 mm diameter and 900 mm length cryoprobe, b) Marks on the distal area of the probe (1 cm between each mark) c) Fogarty baloon d) Cryo-transbronchial lung biopsy samples from one of the patients vs conventional biopsy sample comparison
Patients’ characteristics at baseline and procedural details
| Patient number (n) | 147 | |
| Mean age (years±SD) | 56.4±13 | |
| Gender n (%) Female | 82 (55.8) | |
| Smoking (Pack-years) (n=95, mean±SD) | 12.5±16.8 | |
| CCI (n) 0-2 | 90 | |
| FVC % predicted (Mean±SD) | 82.4±18.5 | |
| DLCO% predicted (Mean) | 59.01±18.1 | |
| Biopsy location | Right lung (n,%) | 134 (91.2) |
| Left lung (n,%) | 13 (8.8) | |
| One segment | 73 | |
| Two different segments | 69 | |
| Three different segments | 5 | |
| Mean biopsy number (n±SD) | 3.3±1 | |
| Freezing duration (seconds, min-max) | 4.8±1.2 s (4-10) | |
| Small axis diameter (mm±SD) | 2.8±0.6 | |
| Large axis diameter (mm±SD) | 6.9±2.3 | |
CCI Charlson Comorbidity index, FVC: Forced vital capacity, DLCO: Carbon monoxide diffusion capacity, cTBB: Transbronchial lung cryobiopsy, SD: standard deviation
Histopathological and multidisciplinary diagnoses and diagnostic yield
| DIAGNOSIS | HISTOPATHOLOGICAL DIAGNOSIS | Non-Specific Interstitial Pneumonia | 46 (46.9) |
| Hypersensitivity Pneumonia | 6 (6.1) | ||
| Usual Interstitial Pneumonia | 6 (6.1) | ||
| Organizing Pneumonia | 6 (6.1) | ||
| Granulomatous Inflamation | 14 (14.3) | ||
| Malignancy | 12 (12.2) | ||
| Othersa | 8 (8.2) | ||
| Non-diagnostic | 49 | ||
| MULTIDISCIPLANARY COUNCIL DIAGNOSIS | Non-Specific Interstitial Pneumonia | 38 (34.8) | |
| Hypersensitivity Pneumonitis | 20 (18.3) | ||
| Idiopathic pulmonary fibrosis | 4 (3.7) | ||
| Sarcoid | 12 (11) | ||
| Organizing Pneumonia | 7 (6.4) | ||
| Malignancy | 12 (12.2) | ||
| Othersb | 15 (13.8) | ||
| Non-diagnostic | 38 | ||
Othersa: Alveolar microlithiasis (1), Non-spesific inflammation (1), Mosaic pattern (1), Histiocytosis X (1), Folicular bronchiolitis (1), Chronic eosinophilic pneumonia (1), Acute Lung Injury (1), Unclassifiable interstitial lung disease (1)
Othersb: Rheumatoid lung disease (1), Tuberculosis (1), Drug induced lung disease (1), Alveolar microlithiasis (1), Nonresolving pneumonia (1), Mosaic attenuation (1), Histiocytosis X (1), Follicular bronchiolitis (1), Acute interstitial pneumonia (1), Unclassifiable interstitial lung disease (1)
SD: standard deviation
Diagnostic yield according to the number of samples
| Pathological diagnosis | 66.6 | 20 (64.51%) | 78 (67.2%) | 0.995 | ||
| 1 biopsy (n=10) | 2 biopsy (n=21) | p=0.244* | ||||
| Diagnosis with Multidisciplinary comittee | 74.1 | 23 (74.1%) | 86 (74.1%) | 0.775 | ||
| 1 biopsy (n=10) | 2 biopsy (n=21) | p=0.034* | ||||
*p value of the comparison between 1 and 2 biopsies
**p value of the comparison between 1-2 and ≥3 biopsies.
Safety outcomes and length of hospital stay (n=147)
| Pneumothorax | 23/147 (total) |
| Hemorrhage | Grade 1: 28/147 (19) |
| Respiratory failure | 3/147 (2.0) |
| Mortality within 30 days | 1/147 (0.7) |
| Length of Hospital stay | 114 (77.5) |